{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:03:51Z","timestamp":1767668631032,"version":"3.48.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.1097\/cm9.0000000000003832","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:00:37Z","timestamp":1761969637000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of novel therapies for refractory and relapsed multiple myeloma in China"],"prefix":"10.1097","volume":"139","author":[{"given":"Jie","family":"Xu","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"},{"name":"Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University, Shanghai 200240, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwei","family":"Jin","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"},{"name":"Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyan","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"},{"name":"Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Affairs, Legend Biotech, Nanjing, Jiangsu 211112, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, Department of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"},{"name":"Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Shanghai 200025, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"R1-20260106","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006\u20132016: An analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R2-20260106","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R3-20260106","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: A national population-based analysis","volume":"9","author":"Wang","year":"2019","journal-title":"Front Oncol"},{"key":"R4-20260106","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"R5-20260106","first-page":"301","article-title":"Multiple myeloma: Charging toward a bright future","volume":"57","author":"Katzel","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R6-20260106","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s12325-014-0159-z","article-title":"Improved response rates with bortezomib in relapsed or refractory multiple myeloma: An observational study in Chinese patients","volume":"31","author":"Lin","year":"2014","journal-title":"Adv Ther"},{"key":"R7-20260106","first-page":"1277","article-title":"Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients","volume":"8","author":"Wang","year":"2015","journal-title":"Onco Targets Ther"},{"key":"R8-20260106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.785774","article-title":"Daratumumab prevents experimental xenogeneic graft-versus-host disease by skewing proportions of T cell functional subsets and inhibiting T cell activation and migration","volume":"12","author":"Gao","year":"2021","journal-title":"Front Immunol"},{"key":"R9-20260106","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00277-022-04951-3","article-title":"Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: A phase 1, dose-escalation study (MMY1003)","volume":"101","author":"Jing","year":"2022","journal-title":"Ann Hematol"},{"key":"R10-20260106","first-page":"210","article-title":"CAR T cells show superiority over standard therapies for RRMM","volume":"20","author":"Killock","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20260106","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"R12-20260106","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T03:00:08Z","timestamp":1767668408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003832","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"type":"print","value":"0366-6999"},{"type":"electronic","value":"2542-5641"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2025-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}